MOBIO INTERACTIVE

Precision Psychiatry at Scale

The Problem

It is exceptionally difficult to deliver precision psychiatry at scale.

The Solution

MI combines computer vision, AI and clinically validated psychotherapy in a single, easy-to-use mobile platform.

Opportunity and Impact

Globally, more than 1 in 10 people need mental health therapy. Digital therapies for mental illness will reach $500 billion/yr by 2035. As an early leader, MI aims to capture 10% of this market while being the first in history to achieve precision psychiatry at scale.

Competitive Advantage

- World's most accurate objective quantification of stress from mobile selfie video (>80% accuracy)
- >2.5 million digital biomarker data points from >25k individual from 175 countries
- Clinically validated therapy

Milestones

- 19Q1: Clinical val., anxiety
- 19Q2: 1st insurer & pharma partners
- 20Q2: Clinical val., psycho-oncology
- 20Q3: Seed raise (oversubscribed)
- 21Q2: Clinical val., multilingual
- 21Q3: 1st hospital partner
- 21Q4: Mode of action study launched
- 22Q1: FDA pre-sub accepted
- 22Q3: EHR integration
- 22Q3: FDA Breakthrough designation
- 23Q1: FDA clearance

UPCOMING

Traction

Established clients across three target verticals: Health Systems, Payors and Pharma

gsc green shield canada   Sun Life Financial   camh Centre for Addiction and Mental Health   CHEO

Breakthrough designation pending

FDA

Respected institutional investors

SOSV   VERGE

mobiointeractive.com
mi@mobiointeractive.com

MOBIO INTERACTIVE